Molecularly targeted agent

Walker I, Newell H (2009) Do molecularly targeted agents in oncology have reduced attrition rates Nat Rev Drug Discov 8 15-16... 

Integration of new specific molecular-targeted agents into multimodality therapy... 

The availability of new molecular approaches to the selection of drug therapy is an emerging need, because the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many treated patients do not experience significant benefits from the treatment, while they often experience moderate to severe toxicities. In addition, the development and clinical use of novel molecularly targeted agents (alone or in combination with classical cytotoxic therapy) requires the understanding of the molecular features of the tumors and the identification of tumor markers of response. 

Kummar S, Gutierrez M, Doroshow JH, et al. Drug development in oncology classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol. 2006 62(1) 15-26. 

The molecular targeting agent (C) selected from a representative sequence of amino acids, resulting in uptake of the triade system particular in the tumor cells. 

Drug Development Paradigms for Molecularly Targeted Agents... 

LorioL Y, Perlemuter, G., Malka, D., Penault-Lorca, F., Boige, V., Deutsch, E., Massard, C., Armand, J. R, and Soria, J.-C.. 2008. Drug insight gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract, 5(5) 26 21S. 

---